Emergent BioSolutions (EBS): 3 Key Points From NDR - Chardan

Chardan Capital Markets analyst, Keay Nakae, reiterated his Buy rating on shares of Emergent BioSolutions (NYSE: EBS) after hosting a non deal roadshow with company management.

3 Key Points:
1) The CDC for BioThrax finally completed in December, along with the new separate contracts from
BARDA.
2) Management has good visibility regarding future revenue for its most important product over the next 3 years.
3) The Company plans to deliver approximately 9 million doses of BioThrax in 2017, which would consist of the 3.2 million doses under the BARDA contract and about 6 million doses delivered under the CDC contract.

No change to the price target of $47.

For an analyst ratings summary and ratings history on Emergent BioSolutions click here. For more ratings news on Emergent BioSolutions click here.

Shares of Emergent BioSolutions closed at $30.15 yesterday.

You May Also Be Interested In

• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
• Adobe (ADBE) PT Lowered to $225 at UBS Amid Plans to Pivot to Freemium Model
• Seneca Foods (SENEA) PT Raised to $202 at Freedom Broker